Ferric Carboxymaltose (Ferinject)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses ferric Carboxymaltose (Ferinject), 50 mg elemental iron/mL, vial for injection (2 mL, 10 mL, 20 mL). Indication: For the treatment of iron deficiency (ID) in adult patients with heart failure and New York Heart Association (NYHA) class II or class III to improve exercise capacity. The diagnosis of ID must be based on laboratory tests.